- Diagnostic Différentiel
Drug Information for Femring (estradiol acetate vaginal ring) (Warner Chilcott (US), LLC): ADVERSE REACTIONS
- WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA FOR ESTROGEN-ALONE THERAPY
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- PATIENT INFORMATION
- TRADE CARTON - Femring 0.05 mg
- SAMPLE CARTON - Femring 0.05 mg
- TRADE CARTON - Femring 0.10 mg
- SAMPLE CARTON - Femring 0.10 mg
- Liens externes liés à Femring (estradiol acetate vaginal ring) (Warner Chilcott (US), LLC)
See BOXED WARNINGS, WARNINGSand PRECAUTIONS.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a 13-week clinical trial that included 225 postmenopausal women treated with Femring and 108 women treated with placebo vaginal rings, adverse events that occurred at a rate of = 2 percent are summarized in Table 6.
Table 6. Incidence of AEs Occurring in = 2% of Subjects Presented in Descending Frequency of Preferred Term AE = adverse event; NOS = not otherwise specified Adverse Event
Placebo(n = 108)
0.05 mg/day(n = 113)
0.10 mg/day(n = 112)
n (%) n (%) n (%) Headache (NOS) 10 (9.3) 8 (7.1) 11 (9.8) Intermenstrual Bleeding 2 (1.9) 9 (8.0) 11 (9.8) Vaginal Candidiasis 3 (2.8) 7 (6.2) 12 (10.7) Breast Tenderness 2 (1.9) 7 (6.2) 12 (10.7) Back Pain 4 (3.7) 7 (6.2) 4 (3.6) Genital Disorder Female (NOS) 9 (8.3) 3 (2.7) 3 (2.7) Upper Respiratory Tract Infection (NOS) 6 (5.6) 5 (4.4) 4 (3.6) Abdominal Distension 3 (2.8) 8 (7.1) 3 (2.7) Vaginal discharge 9 (8.3) 2 (1.8) 3 (2.7) Vulvovaginitis (NOS) 7 (6.5) 6 (5.3) 1 (0.9) Nausea 5 (4.6) 3 (2.7) 2 (1.8) Arthralgia 4 (3.7) 2 (1.8) 2 (1.8) Sinusitis (NOS) 2 (1.9) 2 (1.8) 4 (3.6) Uterine Pain 1 (0.9) 2 (1.8) 5 (4.5) Nasopharyngitis 3 (2.8) 2 (1.8) 2 (1.8) Pain in Limb 3 (2.8) 1 (0.9) 3 (2.7) Urinary Tract Infection (NOS) 2 (1.9) 1 (0.9) 4 (3.6) Vaginal Irritation 4 (3.7) 1 (0.9) 2 (1.8)
- A few cases of toxic shock syndrome (TSS) have been reported in women using vaginal rings. TSS is a rare, but serious disease that may cause death. Warning signs of TSS include fever, nausea, vomiting, diarrhea, muscle pain, dizziness, faintness, or a sunburn-rash on face and body.
- A few cases of ring adherence to the vaginal or bladder wall, making ring removal difficult, have been reported in women using vaginal rings. Patients should be carefully evaluated for vaginal or bladder wall ulceration or erosion. If an ulceration or erosion has occurred, consideration should be given to leaving the ring out and not replacing it until healing is complete to prevent the ring from adhering to the vaginal tissue.
- A few cases of bowel obstruction associated with vaginal ring use have been reported. Persistent abdominal complaints consistent with obstruction should be carefully evaluated.
- A few cases of inadvertent ring insertion into the urinary bladder, which may require surgical removal, have been reported for women using vaginal rings. Persistent unexplained urinary symptoms should be carefully evaluated.
The following additional adverse reactions have been identified during post-approval use of Femring. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
1. Genitourinary system
Uterine cancer, vaginal hemorrhage, ovarian cyst, irregular menstruation, metrorrhagia, menorrhagia, dysmenorrhea, uterine enlargement.
Breast cancer, fibrocystic breast disease, breast disorder, breast mass, breast enlargement, breast pain, nipple pain, breast discharge.
Chest pain, increased blood pressure, irregular heart rate, pulmonary embolism, cerebrovascular accident (stroke), hemiparesis, transient ischemic attack, thrombosis.
Abdominal pain, pancreatitis, cholecystitis, cholelithiasis, vomiting.
Generalized erythema, erythema multiforme, erythema nodosum, rash, hirsutism, pruritis.
Blindness, contact lens intolerance.
7. Central Nervous System
Dizziness, headache, depression, nervousness, mood disturbances, irritability.
Medical device complication, back pain, angioedema, weight increased/decreased, edema, libido increased/decreased, urticaria, hypersensitivity, anaphylaxis.
- Drug Information Provided by National Library of Medicine (NLM).